MARGINAL ZONE LYMPHOMA

This early study tests an experimental drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or stopped responding to treatment. The drug is a BTK degrader, which means it helps break down a protein that cancer cells need to grow. The main …

This phase II trial tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma, a rare blood cancer. The study aims to see how many patients achieve complete remission after one year and how long they stay cancer-free. About 175 par…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and tafasitamab, in 26 people with marginal zone lymphoma that has returned or not improved after previous treatment. The goal is to see how well the combo shrinks tumors and to check its safety. Participants…

This study tests a drug called epcoritamab in Japanese patients whose B-cell lymphoma has returned or not responded to treatment. The drug works by helping the immune system find and attack cancer cells. The trial has two parts: first, finding a safe dose, and then checking how w…

This phase 2 trial is testing a combination of two immunotherapy drugs, glofitamab and obinutuzumab, as the first treatment for people with follicular lymphoma or marginal zone lymphoma. The study includes 47 participants who have not had prior therapy for their lymphoma. The goa…

This study is testing a drug called acalabrutinib, alone or together with other drugs (rituximab and lenalidomide), in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see how safe these combinations are and whether they can…

This early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks …

This early-phase study tests a new type of CAR T-cell therapy that targets three different markers on cancer cells (CD19, CD20, and CD22) to treat people with B-cell lymphomas that have come back or not responded to standard treatments. About 15 adults will receive these speciall…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This early-phase trial tests a combination of two drugs—copanlisib and nivolumab—in people with Richter's transformation or certain non-Hodgkin lymphomas that have become aggressive. The study aims to find the best dose and check for side effects. A total of 27 participants will …

This early-stage trial tests whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody—is safe and can shrink tumors in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to prior treatments. About 24 participan…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…

This study tests a new drug called orelabrutinib for people with B-cell blood cancers (like lymphoma or leukemia). The goal is to see if the drug can shrink tumors and control the disease, while checking for side effects. About 81 adults with relapsed or hard-to-treat cancers wil…

This study tests the safety and effectiveness of tafasitamab, given alone or with other drugs (lenalidomide, parsaclisib, or R-CHOP), in about 72 Japanese adults with Non-Hodgkin lymphoma. The goal is to find the best doses and see if the treatment shrinks tumors. Participants ha…

This study tests whether adding the drug tafasitamab to a standard two-drug combination (lenalidomide plus rituximab) can help people with relapsed or refractory follicular lymphoma or marginal zone lymphoma live longer without their cancer getting worse. About 654 adults who hav…

This study tests a new drug called ARQ 531 (nemtabrutinib) in about 190 people with blood cancers like lymphoma or leukemia that have returned or not responded to other treatments. The goal is to check the drug's safety and how well it works. Participants take the drug as a table…

This study tests obinutuzumab, a targeted antibody, in 56 people with newly diagnosed marginal zone lymphoma who cannot have or have failed local therapy. The goal is to see if this drug can shrink tumors effectively without the harsh side effects of chemotherapy. Participants re…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study tests a new chemotherapy-free treatment for marginal zone lymphoma, a slow-growing blood cancer. It combines two drugs, Copanlisib and Rituximab, to see if they can control the disease better than Rituximab alone, while avoiding harsh chemo side effects. The trial incl…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to be…

This study reviews medical records and PET scans from nearly 500 people with marginal zone lymphoma to see how well PET scans help doctors stage the disease and predict how patients will do. Researchers will compare PET results with CT scans and other tests. The goal is to improv…